Diagnostic efficacy of pan-immune inflammation value for ulcerative colitis activity: a study based on multi-indicator comparison and diagnostic grey zone validation

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

J Gastroenterol Hepatol

Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X

doi: 10.1111/jgh.70634

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Gastrointestinal CancerInflammatory Bowel Disease

Background Mucosal Inflammation Affects Colorectal Cancer Prognosis in Ulcerative Colitis: A Nationwide, Multicenter Study

J Crohns Colitis

Ikebata A, Okabayashi K, Uchino M, Ikeuchi H, Shigeta K, Oka S, Futami K, Itabashi M, Watanabe K, Shibutani M, Okita Y, Wakai T, Mizuuchi Y, Okamoto K, Yamada K, Sato Y, Ogino T, Kimura H, Takahashi K, Hida K, Kinugasa Y, Ishida F, Okuda J, Daito K, Yamamoto T, Yamamoto S, Koyama F, Hanai T, Komori K, Shida D, Arakaki J, Akagi Y, Yamaguchi S, Ueno H, Matsuda K, Maemoto A, Nezu R, Sasaki S, Sunami E, Maeda K, Noake T, Hasegawa J, Kanemitsu Y, Katsumata K, Uehara K, Kiyomatsu T, Suto T, Kazama S, Yamada T, Goi T, Noguchi T, Ishihara S, Ajioka Y, Sugihara K

doi: 10.1093/ecco-jcc/jjaf207

Inflammatory Bowel Disease

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Lancet Gastroenterol Hepatol

Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group

doi: 10.1016/S2468-1253(25)00291-2

Inflammatory Bowel Disease

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Inflamm Bowel Dis

Sands BE, Clemow DB, D'Haens G, Irving PM, Kobayashi T, Peyrin-Biroulet L, Samaan K, Gaur A, Arora R, Todd K, Moses R, Dignass A

doi: 10.1093/ibd/izag007

Inflammatory Bowel Disease

Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN

J Crohns Colitis

Trivić Mažuranić I, Aloi M, Bramuzzo M, Chiantese C, D'Arcangelo G, Gattenlöhner S, Gianolio L, Granot M, Hızarcıoğlu Gülşen H, Hussey S, Kang B, Kolho KL, de Laffolie J, Lega S, Martinelli M, Matar M, Mayer C, Miele E, Norsa L, Panarese I, Rinawi F, Rohani P, Romano C, Sansotta N, Scarallo L, Shouval DS, Staiano A, Strisciuglio C, Tomas D, Yerushalmy-Feler A, Zojaji R, Hojsak I

doi: 10.1093/ecco-jcc/jjag074

Further Publications

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

United European Gastroenterol J

Hart A, Navabi S, D'Haens G, Matsuoka K, Martín-Arranz MD, Atreya R, Samaan KH, Dhesi E, Redondo I, Zhu B, Paulissen J, Zaremba-Pechmann L, Baygani S, Limdi J, Laharie D, Danese S

doi: 10.1002/ueg2.70214

Related content

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Background Mucosal Inflammation Affects Colorectal Cancer Prognosis in Ulcerative Colitis: A Nationwide, Multicenter Study

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis